Synthomer Share Price (SYNT)

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Synthomer Plc LSE:SYNT London Ordinary Share GB0009887422 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -24.80 -5.56% 421.00 1,590,268 16:29:50
Bid Price Offer Price High Price Low Price Open Price
421.00 421.40 446.60 420.40 446.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 1,459.10 100.50 21.50 19.6 1,789
Last Trade Time Trade Type Trade Size Trade Price Currency
17:11:21 O 83,370 446.00 GBX
Related Shares
Croda (CRDA), Johnson Matthey (JMAT), Carclo (CAR), React (REAT)

Synthomer (SYNT) Latest News

Synthomer News

Date Time Source Headline
14/1/202111:05ALNCSynthomer Starts Search For New CEO, Raises Annual Earnings Guidance
14/1/202107:00UKREGSynthomer PLC Pre-Close Trading Update and Board Update
12/1/202109:37UKREGSynthomer PLC Holding(s) in Company
06/1/202109:10UKREGSynthomer PLC Director Declaration
04/1/202110:09UKREGSynthomer PLC Director Declaration
23/12/202020:33ALNCDIRECTOR DEALINGS: New Synthomer Chair Johnstone Buys Shares
23/12/202016:54UKREGSynthomer PLC Director/PDMR Shareholding
17/12/202016:29ALNCUK EXECUTIVE CHANGE SUMMARY: Kingspan Insulation Boards MD To Depart
17/12/202007:00UKREGSynthomer PLC Appointment of New Chair
18/11/202007:00UKREGSynthomer PLC Investor Seminar
More Synthomer News
Synthomer Investors    Synthomer Takeover Rumours

Synthomer (SYNT) Discussions and Chat

Synthomer Forums and Chat

Date Time Title Posts
15/1/202117:50Synthomer393
07/8/201818:23Synthomer (SYNT) One to Watch on Monday 1

Add a New Thread

Synthomer (SYNT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
18:40:31446.0083,370371,830.20O
18:29:08446.0076,566341,484.36O
18:28:54446.003,61116,105.06O
17:11:21420.993,61415,214.61O
17:02:06438.63133583.38O
View all Synthomer trades in real-time

Synthomer (SYNT) Top Chat Posts

DateSubject
15/1/2021
08:20		Synthomer Daily Update: Synthomer Plc is listed in the Chemicals sector of the London Stock Exchange with ticker SYNT. The last closing price for Synthomer was 445.80p.
Synthomer Plc has a 4 week average price of 420.40p and a 12 week average price of 367p.
The 1 year high share price is 466.60p while the 1 year low share price is currently 182.30p.
There are currently 424,850,961 shares in issue and the average daily traded volume is 1,411,153 shares. The market capitalisation of Synthomer Plc is £1,788,622,545.81.
Read Full Thread
Reply
14/1/2021
16:52		sphere25: That was a fascinating battle between the aforementioned profit upgrade and the value of the CEO. You can see the indecisive nature of the market by the intraday move but it appears to be a stalemate with the price closing pretty much bang on flat on the day. I guess that means the market isn't taking it agiven that a new CEO will balls things up here - could be wrong of course. 460p will be a key point to watch for the breakout, kept getting sellers above there to stop the breakout so if the markets don't correct that will be a key mark to watch but more a buyer on any market correction now short term. I think this will test £5 this year so one I'll be keeping an eye on. All imo DYOR
Read Full Thread
Follow
Reply
14/1/2021
08:44		sphere25: So the upgrade has come and with confidence in further growth, it is difficult to rule out another upgrade here imo. Ordinarily this smashes through that recent high for another big breakout but the interesting tussle today is clearly that of forecast upgrade vs the market's perceived value of the CEO. Who will win that battle? Price is currently testing recent highs. Still looks very much a buy the dips play. All imo DYOR
Read Full Thread
Follow
Reply
11/1/2021
10:14		philanderer: JPMORGAN RAISES SYNTHOMER PRICE TARGET TO 500 (450) PENCE - 'OVERWEIGHT'
Read Full Thread
Follow
Reply
07/12/2020
10:15		philanderer: BOFA RAISES SYNTHOMER PRICE TARGET TO 440 (400) PENCE - 'NEUTRAL'
Read Full Thread
Follow
Reply
27/10/2020
00:11		philanderer: Synthomer PLC (LON:SYNT) was upgraded to ‘overweight217; from ‘neutral’; by JP Morgan after analysts looked at the company’s exposure to the gloves market. The polymer, sealant and chemicals specialist sells nitrile latex for nitrile gloves, a business which accounted for around 20% of 2019 group earnings. The main manufacturer in the sector, Top Glove, recently indicated that their lead time for nitrile gloves has extended significantly to 660 days compared to the average pre-pandemic lead time of 30-40 days. The US investment bank said gloves demand will moderate as COVID-19 vaccines become widely available, which may not be until the second half of 2021 or 2022, though it is also possible that the greater focus on hygiene might result in structurally higher gloves demand in the future. “We believe that both the magnitude and the duration of this upside is likely to be better than the market assumes,” analysts noted, while raising the target price to 450p. “There is a potential of further significant upside as we have significantly discounted the potential tailwind that we calculate from the substantial step-up seen in nitrile prices/spreads due to tight supply.” proactiveinvestors.co.uk/
Read Full Thread
Follow
Reply
21/10/2020
09:17		philanderer: JEFFERIES RAISES SYNTHOMER PRICE TARGET TO 440 (370) PENCE - 'BUY' MORGAN STANLEY RAISES SYNTHOMER TARGET TO 380 (350) PENCE - 'EQUAL-WEIGHT'
Read Full Thread
Follow
Reply
19/10/2020
09:08		philanderer: BERENBERG RAISES SYNTHOMER PRICE TARGET TO 430 (370) PENCE - 'BUY'
Read Full Thread
Follow
Reply
07/10/2020
10:37		philanderer: UBS RAISES SYNTHOMER PRICE TARGET TO 325 (305) PENCE - 'NEUTRAL'
Read Full Thread
Follow
Reply
13/8/2020
11:00		philanderer: UBS today reaffirms its neutral investment rating on Synthomer (LON:SYNT) and raised its price target to 305p (from 285p).
Read Full Thread
Follow
Reply
15/9/2019
08:21		robow: GREAT IDEAS 10 | SHARES | 12 September 2019 Chemicals firm Synthomer (SYNT) looks very tempting at the current price following a big sell-off over the past year. The firm’s share price dropped from around 530p a year ago to 280p last month and saw the stock trade on nearly its lowest rating in a decade, while its level of debt compared to how much it’s earning is expected to double. But with the business on the cusp of global expansion as it aims to keep up with soaring demand for its products, investors with a long-term view may want to take advantage of the firm’s cheap valuation. The chemicals sector has historically been a good place to invest with significant share price gains over the past decade and occasionally generous dividends. But chemicals companies have been caught up by concerns over a global economic slowdown in the past year, and some in the market think this may feed into weaker demand for chemicals products. Synthomer has tried to expand significantly to keep up with demand for its speciality products, sought after due to many factors such as urbanisation, ageing demographics and stricter legislation. The firm supplies aqueous polymers to companies, which The company should benefit from capacity expansion and a deal to boost its position in the US and Europe The outlook is looking brighter for Synthomer Synthomer is also forecast by analysts at Canaccord and Numis to have a much stronger second half of this year as market conditions are set to improve. That combined with its completed upgrades to facilities in Germany and Malaysia means the firm will have greater capacity to meet demand for its products. Its net debt-to-earnings ratio is expected to increase next year to between 2.2 and 3-times as the Omnova deal is completed. But Synthomer has a clear plan to get this down below 2-times by the end of 2021. Its management team has a disciplined approach to M&A, with a ‘conservative capital’ policy meaning it’s unlikely to ever be reckless in the pursuit of growth. help create new products and boost the performance of existing ones, such as footwear insoles, condoms, packaging tapes, carpets and waterproofing products. While strong on the consumer side, investors had questioned Synthomer’s growth prospects given its lack of real penetration into the industrial market. But the proposed deal to acquire Omnova Solutions, an American speciality chemicals business operating in sectors like construction and oil and gas, could make the market reappraise Synthomer. As well as the US, Omnova has manufacturing and technical facilities in Europe, Thailand and China. Analysts at UBS believe the acquisition will help Synthomer sell more products in the US, and help it expand its facilities in Europe. SYNT is also forecast by analysts at Canaccord and Numis to have a much stronger second half of this year as market conditions are set to improve. That combined with its completed upgrades to facilities in Germany and Malaysia means the firm will have greater capacity to meet demand for its products. Its net debt-to-earnings ratio is expected to increase next year to between 2.2 and 3-times as the Omnova deal is completed. But Synthomer has a clear plan to get this down below 2-times by the end of 2021. Its management team has a disciplined approach to M&A, with a ‘conservative capital’ policy meaning it’s unlikely to ever be reckless in the pursuit of growth. help create new products
Read Full Thread
Follow
Reply
Synthomer share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
SYNT
Synthomer
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210115 18:59:51